Methods for predicting outcome in traumatic brain injury

• US 20060051814A1
• Filed: 08/10/2005
• Published: 03/09/2006
• Est. Priority Date: 08/27/2001
• Status: Abandoned Application

• Current Assignee: Eric B. Stanton, George Jackowski, Michelle Davey, Miyoko Takahashi, Petro Kupchak
• Original Assignee: Eric B. Stanton, George Jackowski, Michelle Davey, Miyoko Takahashi, Petro Kupchak
• Inventors: Jackowski, George, Kupchak, Petro, Takahashi, Miyoko, Davey, Michelle, Stanton, Eric B.
• Application Number:
  US11/201,349
• Publication Number:
  US 20060051814A1
• Time in Patent Office: Days
• US Class Current: 435/7.100
• CPC Class Codes: A61B 6/501 for diagnosis of the head, e.g. neuroimaging or craniography
• CPC Class Codes: G01N 2333/988 Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
• CPC Class Codes: G01N 33/6896 Neurological disorders, e.g. Alzheimer's disease

Abstract

The invention describes methods for predicting outcome for patients suffering from traumatic brain injury (TBI) by evaluating levels of markers commonly associated with cellular damage in bodily fluids. Utilization of such methods improves diagnosis and treatment of patients suffering from traumatic brain injury, thus potentially minimizing and/or eliminating long-term adverse effects in these patients.

Claims

1. A method for predicting outcome for a subject suffering from traumatic brain injury (TBI) comprising the steps of;

(a) obtaining a sample of body fluid from said subject;

(b) contacting said sample of body fluid with an antibody that specifically binds a β

subunit of S-100 protein, said antibody immobilized on a solid support; and

(c) determining binding of said antibody to said β

subunit of S-100 protein in said sample of body fluid wherein a level of said β

subunit of S-100 protein elevated above 39 pg/mL predicts outcome for a subject suffering from traumatic brain injury (TBI).

2. The method as in claim 1 wherein said antibody specifically binds the β

subunit in β

β and

α

β

isoforms of S-100 protein.

3. The method as in claim 1 wherein said sample of body fluid is selected from the group consisting of serum, plasma, urine, lymph and cerebrospinal fluid (CSF).

4. The method as in claim 1 wherein said steps of contacting and determining are carried out by immunoassay.

5. The method as in claim 4 wherein said immunoassay is a sandwich enzyme-linked immunosorbent assay (ELISA).

6. A method for predicting the existence of brain injury detected by a computer-assisted tomographic (CT) scan in a subject suffering from traumatic brain injury (TBI) comprising the steps of;

(a) obtaining a sample of body fluid from said subject;

(b) contacting said sample of body fluid with an antibody that binds myelin basic protein (MBP), said antibody immobilized on a solid support; and

(c) determining binding of said antibody to said myelin basic protein (MBP) in said sample of body fluid wherein a level of said myelin basic protein (MBP) elevated above 76 pg/mL predicts the existence of brain injury detected by a computer-assisted tomographic (CT) scan in a subject suffering from traumatic brain injury.

7. The method as in claim 6 wherein said sample of body fluid is selected from the group consisting of serum, plasma, urine, lymph and cerebrospinal fluid (CSF).

8. The method as in claim 6 wherein said steps of contacting and determining are carried out by an immunoassay.

9. The method as in claim 8 wherein said immunoassay is a sandwich enzyme-linked immunosorbent assay (ELISA).